Agenus (NASDAQ:AGEN) Price Target Lowered to $7.00 at HC Wainwright

Agenus (NASDAQ:AGEN) had its target price reduced by HC Wainwright from $8.00 to $7.00 in a research note released on Tuesday,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

A number of other research analysts have also recently commented on AGEN. B. Riley reduced their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. William Blair cut shares of Agenus from an “outperform” rating to a “market perform” rating in a research report on Thursday, July 18th. Baird R W cut shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. Finally, Robert W. Baird cut shares of Agenus from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $10.00.

Agenus Trading Down 8.6 %

NASDAQ AGEN opened at $2.77 on Tuesday. The company’s fifty day simple moving average is $4.74 and its 200-day simple moving average is $8.77. Agenus has a 52 week low of $2.74 and a 52 week high of $19.69. The stock has a market cap of $59.75 million, a P/E ratio of -0.25 and a beta of 1.39.

Institutional Trading of Agenus

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets increased its stake in Agenus by 81.3% during the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 84,477 shares during the last quarter. Vanguard Group Inc. increased its stake in Agenus by 13.7% during the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock valued at $19,953,000 after purchasing an additional 4,134,232 shares during the last quarter. Acadian Asset Management LLC increased its stake in Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock valued at $439,000 after purchasing an additional 720,629 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Agenus by 52.4% during the first quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares during the last quarter. Finally, Ovata Capital Management Ltd bought a new stake in Agenus during the second quarter valued at $670,000. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.